natgillin/translations-raw huggingface dataset:
The pharmaceutical combinations according to the invention may contain (a) and (b) in the case of budesonide, for example, in a ratio by weight (b):(a) ranging from 1:10 to 50:1, preferably from 1:5 to 10:1, preferably 1:4 to 5:1, most preferably from 1:2 to 2:1. 
Farmaceutske kombinacije sukladno predmetnom izumu mogu sadržavati (a) 1 (b) u slučaju formoterola, na primjer u težinskom omjeru (b):(a) u rasponu od 1:10 do 300:1, poželjno od 1:5 do 200:1, poželjno od 1:3 do 150:1, a poželjnije od 1:2 do 100:1.
Trastuzumab-MCC-DM1 for use in the method of claim 2, wherein the HER2-positive breast cancer or gastric cancer has an immunohistochemistry (IHC) score of 2+ or 3+ and/or an in situ hybridization (ISH) amplification ratio ≥2.0. 
Trastuzumab-MCC-DMI1 za upotrebu u postupku prema patentnom zahtjevu 2, naznačen time, da HER2 pozitivan karcinom dojke ili karcinom želuca ima rezultat imunohistokemije (IHC-vrijednost) od 2+ ili 3+ 1/ii amplifikacijski omjer dobiven in situ hibridizacijom (ISH) u iznosu od 2:2,0.
For example, the circuit of Figure 5 could be implemented into a circuit board or printed circuit board. 
Tako, na primjer, kolo sa slike 5 može se izvesti kao montažna ploča ili kao štampana ploča.
The aqueous formulation of claim 5, wherein the analogue of exendin-4 is selected from a group comprising lixisenatide, exenatide and liraglutide. 
Vodena farmaceutska formulacija prema zahtjevu 1 naznačena time da sadrži analog eksendina-4 odabran iz skupine koja sadrži liksisenatid, eksenatid i liraglutid.
The method of claim 5, wherein said condition associated with altered glutamatergic signalling and/or functions, or said condition which can be affected by alteration of glutamate level or signalling is selected from the group consisting of: dementias, parkinsonism and movement disorders, acute or chronic pain, anxiety disorders, schizophrenia, mood disorders, endocrine and metabolic diseases, diabetes, disorders of the endocrine glands, hypoglycaemia, and cancers. 
Spoj prema bilo kojem od zahtjeva 1 do 3 ili farmaceutski sastav prema zahtjevu 5 za uporabu u liječenju ili sprječavanju stanja odabranog od demencija, parkinsonizma i poremećaja kretanja, akutne ili kronične boli, anksioznih poremećaja, šizofrenije, poremećaja raspoloženja, endokrinih i metaboličkih bolesti, dijabetesa, poremećaja endokrinih žlijezda, hipoglikemije ili rakova.
A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 in combination with one or more active agent(s) selected from a corticosteroid, a vitamin D3 derivative, a retinoid, an immunomodulator, an anti-androgen, a keratolytic agent, an anti-microbial, a platinum chemotherapeutic, an antimetabolite, hydroxyurea, a taxane, a mitotic disrupter, an anthracycline, dactinomycin, an alkylating agent and a cholinesterase inhibitor. 
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je u kombinaciji s jednim ili više aktivnih sredstava, koja se bira između kortikosteroida, derivata vitamina D3, retinoida, imunomodulatora, antiandrogena, keratolitičkog sredstva, antimikrobnog sredstva, kemoterapeutika na bazi platine, antimetabolita, hidroksiuree, taksana, inhibitora mitoze, antraciklina, daktinomicina, alkilirajućeg sredstva i inhibitora kolinesteraze.
A process according to claim 8, characterised in that said metal is removed out of the finely milled portion of the coarser slag material fraction by a dry separation process, in particular by a centrifuging process. 
Postupak prema zahtjevu 8, naznačen time što se metal uklanja iz fino mljevenog dijela grublje troske postupkom suhog razdvajanja, posebno centrifugiranjem.
56, 57 and 58; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising respectively the amino acid sequences SEQ ID Nos. 
1,21 3, laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 te sadrži aminokiselinsku sekvenciju SEQ ID No.
The term aryl refers to a carbocyclic aromatic group, such as phenyl or naphthyl, in particular phenyl. 
Termin aril se odnosi na karboksilnu aromatični skupinu poput fenila ili naftila, posebno fenila.
Most preferably, said desired concentration of sodium hydroxide is about 2% sodium hydroxide. 
Najpoželjnija koncentracija natrij hidroksida je oko 2%.
The method according to claim 1, wherein the at least one first additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate. 
Medicinski uređaj prema zahtjevu 1, naznačen time, da tenzid je Tween 20 i kemijski spoj je odabran od sorbitola ili laktobionske kiseline.
As those skilled in the art will appreciate, the number of ridges 102 may be varied from what is depicted so long as the container 101 can stand upright on a substantially flat surface. 
Kako će stručnjaci ovog područja razumjeti, broj izbočenja 102 može se razlikovati od prikazanog sve dok posuda 101 može stajati uspravno na ravnoj površini.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline monosulfate salt of claim 1, in micronized form. 
Farmaceutski sastav koji sadrži farmaceutski prihvatljiv nosač i spoj prema zahtjevu 16.
Liquid pharmaceutical compositions that are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal, and subcutaneous injection. 
Tekući farmaceutski pripravci koji su sterilne otopine ili suspenzije prikladni su za intramuskularnu, intraperitonealnu i supkutanu injekciju.
The process of claim 9, wherein the jet fraction (40) is used directly as a jet fuel without blending; or the diesel fraction is used directly as a diesel fuel without blending. The process of claim 4, wherein: 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da se frakcija mlaznog goriva (40) koristi izravno kao mlazno gorivo bez miješanja; ili se dizelska frakcija koristi izravno kao dizelsko gorivo bez miješanja.
Wind system (1) according to claim 2, characterised in that said trolley (11) is equipped with said wheels (16, 17) to support said trolley (11) weight. 
Vjetreni sustav (1) prema zahtjevu 6, naznačen time da je spomenuta rastegnuta fleksibilna konstrukcija (12) opremljena jednom okomitom rešetkastom konstrukcijom (13).
Y- is selected from the group consisting of 
- Y- se izabire iz skupine koja obuhvaća
cooling the mixed solution/dispersion of step (c) to ambient temperature; 
hlađenje izmiješane otopine/disperzije iz koraka (a), (b), (c) ili (d) da temperature okoline ili ispod;
Example 1 Manufacture of Lozenges General Procedures and Equipment 
Primjer 1 - Proizvodnja tableta-pastila (Opći postupci i oprema)
The compound or salt of claim 9 wherein said JAK is JAK1 or JAK2. 
Spoj ili sol prema zahtjevu 42 naznačen time da navedeni JAK je JAK1 ili JAK2.
G') separating the organic phase from said biphasic solution and, optionally, one or more further extractions of said aqueous phase with an organic solvent; 
G’) odvajanje organske faze od spomenute bifazne otopine i, po izboru, jedna ili više dodatnih ekstrakcija spomenute vodene faze organskim otapalom;
A kit according to claim 13, further comprising a brush for applying the radiation curable gel nail coating composition. 
Komercijalni komplet prema patentnom zahtjevu 13, koji dalje sadrži četkicu za nanošenje pripravaka u vidu gellaka za nokte za čije sušenje se korisiti zračenje.
a group represented by the following formula (II): wherein 
G je predstavljeno sljedećom formulom (III):
The compound of claim 3, wherein the compound of Formula (IV) is the (+)- or (-)-enantiomer. 
Postupak sukladno zahtjevu 1, pri čemu je spoj formule (I) (+)- ili (-)-enantiomer.
water in an amount of about 2% to about 15% by weight of the composition, a lipophilic component, 
vodu u količini od oko 2 masena % do oko 15 masenih % od sastava;
The method of claim 11 wherein the bacterial cells are that of Salmonella minnesota. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što su bakterijske stanice one od bakterije Salmonella minnesota.
a non-ionic emulsifier selected from the group consisting of cetearyl alcohol, ceteareth-12, ceteareth-20 and mixtures thereof, in the range from about 0.5 to 15.0 % w/w; 
neionskog emulgatora izabranog iz grupe koja se sastoji od cetearil alkohola, cetearet-12, cetearet-20 i njihove smjese, u rasponu od 0,5 do 15,0 % wt/wt;
Next, the possible effect of the HMW Zn-HA (10 mg/kg in 200 µl of physiological saline, subcutane) on the time of appearance of clinical symptoms has been investigated. 
Sljedeće, mogući učinak HMW Zn-HA (10 mg/kg u 200 ul fiziološke otopine, subkutano) u vremenu od pojave kliničkih simptoma je bio predmet ispitivanja.
Production of phosphate compounds from materials containing phosphorus and at least one of iron and aluminium 
PROIZVODNJA FOSFATNIH SPOJEVA OD MATERIJALA KOJI SADRŽE FOSFOR I BAREM JEDAN ODABRAN OD ŽELJEZA I ALUMINIJA
a turning force impaction mechanism (250) for a higher speed/lower torque mode including a plurality of turning force impaction transmitters (251, 252); 
udarni mehanizam na bazi sile vrtnje (250) za način rada s većom brzinom i manjim obrtnim momentom koji sadrži više prijenosnika udara sile vrtnje (251, 252);
Experiments were performed under a flow of nitrogen and using a heating rate of 10 °C/min to a maximum temperature of approximately 250 °C. After automatically taring the balance, 5 to 20 mg of sample was added to the platinum pan, the furnace was raised, and the heating program started. 
Ekperimenti su izvođeni pod dušikom pri brzini zagrijavanja od 10 *C/min do maksimalne temperature od približno 250*C. Nakon automatskog postavljanja tare na vagi, 5 do 20 mg uzorka je dodano u platinastu posudu, pećnica je upaljena i programirano zagrijavanje je započelo.
A is an optionally substuted 3-7 membered monocyclic ring; 
A je 3 člani monociklički prsten;
2: Metabolic profile obtained for ST1899 monkey microsomes at 120 minutes in comparison to the basal. 
Slika 2: Metabolički profil dobiven za ST1899 u mikrosomima majmuna na 120 minuta u usporedbi s osnovnim.
reacting the compound of the Formula X with formic acid and formaldehyde or a polymer of formaldehyde, conveniently in water at a temperature in the range of from 70 to 95° C., conveniently 70 to 90° C. to form a formic acid salt of ZD6474; 
O X naznačen time, da navedeni postupak obuhvaća: (n) reakciju spoja formule X sa mravljom kiselinom i formaldehidom ili sa polimerom formaldehida sa svrhom nastajanja soli mravlje kiseline ZD6474;
is hydrogen or alkyl; 
RS je vodik ili alkil;
B1, B2 are independently adenine, guanine, thymine, cytosine, uracil or modified nucleosides; 
B,1iB, su nezavisno adenin, guanin, timin, citozin, uracil ili modificirane nukleobaze.
A dispenser according to any preceding claim, wherein the dispenser cap comprises one or more protrusions in the upper open end of the dispenser cap, the one or more protrusions being arranged to engage with a correspondingly shaped recess in the upper cap closure portion when the dispenser cap is closed by the dispenser closure device. 
Dispenzer u skladu sa patentnim zahtjevom 28 ili 29, gdje element (41) za povezivane sadrži jedan ili više proreza (4504, 450b), 1 pokretač (206) brojača sadrži jedno ili više ispupčenja (222a, 222b) za angažiranje sa elementom za povezivanje da bi se upario element za povezivanje sa pokretačem brojača.
Percussion device as claimed in claim 2 or 3, wherein said anchor (5) is shaped as a hollow cylinder having a diameter of 8-15 mm, preferably of 10 mm, 20-40 mm long, preferably 30 mm long, and with a mass of about 6-17 gr, preferably of 10 gr. 
Sonda temeljem zahtjeva 2 ili 3, naznačena time da je sidro (5) oblikovano kao šuplji cilindar koji ima promjer od 8-15 mm, poželjno 10 mm, duljine 20-40 mm, poželjno 30 mm, i koji ima masu od 6-17 g, poželjno 10 g.
A compound or a salt, a solvate, a tautomer or a stereoisomer thereof according to any of claims 1 to 16, or a composition according to claim 17, for use in treating chronic pain, acute pain, inflammatory pain, neuropathic pain, or bone pain. 
Spoj ili njegova sol, solvat, tautomer ili stereoizomer prema bilo kojem od zahtjeva 1 do 16, ili pripravak prema zahtjevu 17, naznačen time da je za uporabu za liječenje kronične boli, akutne boli, upalne boli, neuropatske boli, ili boli u kostima.
Use of salts comprising pharmaceutically acceptable alkali metal cations for the stabilization of a liquid gonadotropin formulation. 
Uporaba soli koje sadrže farmaceutski prihvatljive katione alkalijskih metala radi ograničavanja tendencije FSH disociranja u tekućoj formulaciji FSH, pri čemu je sol Na2S04 ili kombinaciju NaCl and Na2S04.
The chimeric molecule of claim 18, wherein the ligand is an antibody or fragment thereof which has antigen recognition capability. 
Kimerička molekula 12 zahtjeva 6, nadalje naznačena time da je (a) neko njeno antitijelo ili fragment antitijela koji zadržava sposobnost prepoznavanja antigena.
polynucleotide sequences having at least 75% identity to SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 9 or SEQ ID NO 11 or variants, homologues, fragments or derivatives thereof; and combinations thereof. 
polinukleotidnih sekvenci koje su najmanje 75% identične sa SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10 ili SEQ ID NO 12 ili njihovim varijantama, homolozima, fragmentima ili derivatima i njihovim kombinacijama.
This is particularly desirable for access to data services—in embodiments, means are provided to enable access to data services consistently for some or all subscription network identifiers for the subscribed device. 
Postupak prema bilo kom od prethodnih zahtjeva, koji dalje obuhvaća omogućavanje konzistentnog pristupa servisima za podatke za neke ili za sve pretplatničke mrežne identifikacije za pretplatnički uređaj.
performing, by the computer network (100), a consistency step (40) such that data consistency is realized between the backup copy (B1') and the further backup copy (B2") in dependence of the first and second transaction identifier. 
- < Izvođenje, računalnom mrežom (100) stupanja dosljednosti (40) tako da se između sigurnosne kopije (B1') i druge sigurnosne kopije (B2") ostvaruje konzistentnost podataka ovisno o prvom i drugom pokazatelju prijenosa.
Thus, choosing e.g. 10% by weight as sodium chloride/potassium chloride concentration, preferably 9.5% by weight of sodium chloride and 0.5% by weight of potassium chloride can be applied. 
Dakle, odaberemo li 10% (težinski) kao koncentraciju natrijeva klorida/kalijeva klorida, poželjno valja primijeniti 9,5% (težinski) natrijeva klorida i 0,5% (težinski) kalijeva klorida.
After the 3-hr treatment with and without metabolic activation, medium was aspirated, the cells rinsed with phosphate buffer saline, refed with complete medium and returned to the incubator. Collection of Metaphase Cells 
Poslije 3-satnog tretmana sa i bez metaboličke aktivacije, podloga je usisana, stanice su isprane fosfatno puferiranom slanom otopinom, ponovo je dodana kompletna podloga 1 vraćena u inkubator.
It is also possible to use mixtures of the above-stated hydrophilic and hydrophobic materials as matrix materials. 
Također je moguće kao materijale za matricu primijeniti smjese prethodno navedenih hidrofilnih i hidrofobnih materijala.
A compound for use according to claim 7, wherein the haematological malignancy is acute myeloic leukemia (AML). 
Spoj za uporabu prema patentnom zahtjevu 7, pri čemu je hematološka malignost akutna mijeloična leukemija (AMI).
A compound of formula (I) wherein 
Spoj s formulom (I) [image] pri čemu
a nucleic acid encoding a recombinant co-stimulatory ligand, wherein the co-stimulatory ligand is a cytokine. 
T-stanica prema zahtjevu 1, naznačena time da se T-stanica je nukleinskom kiselinom koja kodira ko-stimulacijski ligand.
A method as claimed in claim 1, further comprising discharging a filtrate passed through the filter band and containing purified water originating from the aqueous fluid into the sea or leading it to the exhaust gas scrubber. 
Postupak prema zahtjevu 1, naznačen time da da filtrat prolazi kroz traku za filtriranje (122) i sadrži pročišćenu vodu koja potječe iz vodene tekućine koja se ispušta u more ili dovodi do pročistača ispušnog plina (1).
The fractions were loaded on the gel according total protein—20 mcg/lane. 
Frakcije su nanesene na gel uz ukupnu koncentraciju proteina - 20 meg/jažici.
The disarming system for disarming the components of an ammunition cartridge (10) according to claim 6, characterized in that at least one of the elements of the disarming system is interchangeable for adapting its operation to different gauges of ammunition cartridges (10). 
Sustav za razoružavanje, namijenjen razoružavanju komponenti čahure streljiva (10) u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačen time što je najmanje jedan od njegovih elemenata međusobno zamjenjiv, radi prilagođavanja njegovog rada različitim kalibrima čahura streljiva (10).
The isolated antibody or antigen-binding portion thereof, of claim 6, which comprises a mutated or chemically modified amino acid Fc region, wherein said mutated or chemically modified Fc region provides increased ADCC activity when compared with the wild type Fc region. 
Protutijelo prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da ono obuhvaća Fc-područje aminokiseline koje je mutirano ili kemijski modificirano, pri čemu spomenuto mutirano ili kemijski modificirano Fc-područje aminokiseline, omogućava povećanje ADCC-djelovanja u usporedbi s divljom vrstom Fc-područja.
A hydrogen sulfate salt of Compound 1 according to claim 1 in the form of a solvate. 
Sol hidrogen sulfata od Spoja 1 prema zahtjevu 1 u obliku solvata.
at least one substantially concave inner surface adapted to receive the user's head in engagement; 
najmanje jednu uglavnom konkavnu unutrašnju površinu (2b) prilagođenu za prihvaćanje korisnikove glave u korištenju;
The multispecific antigen-binding molecule of claim 3, wherein the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site which comprises an L chain variable region consisting of any one of the amino acid sequences selected from the following (c1) to (c10), or an antigen-binding site functionally equivalent thereto: 
mjesta vezanja antigena uključena u treći polipeptid i četvrti polipeptid, obuhvaćaju mjesto vezanja antigena koje obuhvaća varijabilno područje L-lanca koje se sastoji od bilo koje od aminokiselinskih sekvenci odabranih od sljedećih (c1) do (c10):
After stirring at room temperature for 15 minutes, the reaction was quenched by pouring into water (10 mL). 
Nakon miješanja na sobnoj temperaturi tijekom 15 minuta, reakcija se prekine stavljanjem u vodu (10 mL).
A pharmaceutical composition comprising the peptide with SEQ ID NO 1 and the peptide with SEQ ID NO 2, and a pharmaceutically acceptable carrier. 
Peptid koji se sastoji od sekvence koja je odabrana iz grupe SEQ ID br. 4 i SEQ ID br. 5.
5 is a cross-sectional view along the V-V line in FIG. 2, in which the brewing unit is shown in the configuration it takes when a capsule containing the raw material for the beverage is loaded therein; 
Slika 5 je poprečni presjek uz liniju V-V na Slici 2, gdje je jedinica za kuhanje prikazana u konfiguraciji koju poprima kada se u nju stavlja kapsula za držanje sirovine za napitak;
After standing at room temperature overnight, the reaction mixture is poured carefully onto ice water and extracted with DCM (3 x 40ml). 
Nakon stajanja preko noći pri sobnoj temperaturi, reakcijsku smjesu se oprezno prelije na ledenu vodu i ekstrahira s DCM-om (3 x 40 ml).
Compounds of formula I according to claim 1, wherein said heteroaryl at R3 is substituted with halogen, C1-9-alkyl or C1-9-alkyl mono-or bi-substituted with hydroxy. 
Spojevi formule I prema zahtjevu 1, naznačeni time, da je spomenuti heteroaril na R3 supstituiran s halogen, C1-9-alkil ili C1-9-alkil mono- ili bi-supstituiran s hidroksi.
A compound having one of the following structures: and wherein: 
Tvar ima jednu od sljedećih struktura:
baclofen, acamprosate and memantine, or baclofen, acamprosate and gabapentine, or pharmaceutically acceptable salts thereof. 
baklofen, akamprozat i memantin, ili njihove farmaceutski prihvatljive soli.
n is an integer from 1 to 6; 
gdje q je cijeli broj od 1 do 5;
wherein: X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; 
R4 naznačen time što: X predstavlja dva atoma vodika, atom sumpora, atom kisika ili C,.» alkilnu skupinu i atom vodika;
is hydrogen, halogen, C1-3 alkyl or C1-3 alkoxy, wherein said alkyl or alkoxy is unsubstituted or substituted with one or more halogen atoms; 
je vodik, halogen, C1-3 alkil ili C1-3 alkoksi, pri čemu je navedeni alkil ili alkoksi nesupstituiran ili supstituiran s jednim ili više atoma halogena;
a demodulator (r104) for demodulating the received signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; 
demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM);
Preferably, in the processes according to the invention, pieces of wood are employed having a comparatively high (relative) wood humidity. 
Poželjno je da, u postupku koji je u skladu s ovim izumom, komadi od drva koji se ovdje koriste imaju relativno visoku (relativnu) vlažnost drva.
A compound of any one of claims 1-34 or a pharmaceutically acceptable salt or ester thereof, or composition thereof for use in the therapeutic or prophylactic treatment of a Pneumovirinae virus infection or a respiratory syncytial virus infection. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-34 ili njegova farmaceutski prihvatljiva sol ili ester, ili njegova kompozicija za primjenu u terapijskom ili profilaktičkom tretmanu Pneumovirinae virusne infekcije ili respiratorne sincicijske virusne infekcije.
Formula (I) compounds: wherein 
Spojevi formule (I): u kojima
A glycosylated human Serum Amyloid P (SAP) polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Farmaceutski pripravak, naznačen time, da sadržava rekombinantni glikolizirani humani serumski amiloidni P (SAP) polipeptid koji sadržava N-vezani oligosaharidni lanac, pri čemu barem jedna grana oligosaharidnog lanca završava s a2,3-vezanim ostatkom sijalične kiseline i pri čemu smjesa ima najmanje 50% manje a2,6-vezanih ostataka sijalinske kiseline od divljeg tipa SAP izoliranog iz humanog seruma.
The method according to claim 19 wherein the antioxidant/free radical scavenger agent is selected from the group consisting of nicaraven, ranolazine, emoxipin, glutathione, edaravone, raxofelast, lycopene, N-acetyl-L-cysteine, N-acetyl-D-cysteine, a racemic mixture of N-acetyl-L-cysteine and N-acetyl-D-cysteine, and carvedilol. 
Upotreba prema bilo kojem zahtjevu 18 do 30, naznačena time, da farmaceutski sastav nadalje sadrži antioksidant/sredstvo za hvatanje slobodnih radikala, ponajprije nikaraven, ranolazin, emoksipin, glutation, cdaravon, raksofclast, likopen, N-accetil-1-cistcin, N-acctil-D-cistcin, racemičnu smjesu N-acctil-1-cisteina i N- acetil-D-cisteina ili karvedilol.
The antibody according to any one of claims 1 to 7, wherein the antibody inhibits the phosphorylation of EPHA2 tyrosine residues induced by an EPHA2 ligand. 
Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1 do 6, gdje antitijelo inhibira fosforilaciju EPHA2 tirozinskih ostataka induciranu pomoću liganda EPHA2.
trigger cam means (26, 27; 126, 127) pivotable integrally with said drive cam means and connected operatively with said plunger means (8; 108) to angularly displace said plunger means (8; 108) to said trigger positions of the first dose and the at least second dose, 
- ekscentrični aktivator (26, 27; 126, 127) koji se može zakretati zajedno s ekscentričnim sklopom za pokretanje 1 povezan operativno s navedenim klipom (8; 108) kako bi pod kutom potisnuo navedeni klip (8; 108) do navedenih položaja za aktiviranje prve doze i najmanje druge doze,